Lifestyle Modifications for Hyperlipidemia Management

Lipid Management Through Lifestyle Modifications

The American Heart Association recommends reducing saturated fat intake to <7% of total calories to manage hyperlipidemia 1, 2
Limiting cholesterol intake to <200 mg/day is advised for patients with hyperlipidemia 1, 2
Restricting trans fatty acids to <1% of total calories is recommended for lipid management 1, 3
Increasing consumption of fresh fruits, vegetables, and low-fat dairy products can help manage hyperlipidemia 1, 4
Replacing saturated fats with monounsaturated fats (olive oil, canola oil) and polyunsaturated fats (corn oil, peanuts) can lower LDL without adversely affecting HDL 2
Adding plant stanols/sterols (2 g/day) and viscous fiber (>10 g/day) can further lower LDL-C 1, 3
Considering omega-3 fatty acids from fish or fish oil capsules (1 g/day) for cardiovascular risk reduction is recommended 1, 4

Engaging in at least 30 minutes of moderate-intensity physical activity on most days of the week is recommended for hyperlipidemia management 1, 4
Increasing daily physical activity as part of comprehensive lifestyle modification is advised 1, 2

Achieving and maintaining a BMI between 18.5 and 24.9 kg/m² is recommended for patients with hyperlipidemia 4
Maintaining waist circumference <35 inches for women is advised 4
Weight control is strongly recommended for all patients with hyperlipidemia 1, 2

The American College of Cardiology recommends LDL-C goals based on cardiovascular risk category, with goals of <160 mg/dL for patients with 0-1 risk factors, <160 mg/dL for patients with 2+ risk factors and 10-year risk <10%, <130 mg/dL for patients with 2+ risk factors and 10-year risk 10-20%, and <100 mg/dL for patients with CHD or CHD equivalent 2
Implementing therapeutic lifestyle changes for 12 weeks before considering pharmacotherapy is recommended 2
Monitoring lipid profile at least annually, more frequently if needed, is advised to assess progress toward goals 5

Treating iron deficiency with appropriate iron supplementation based on severity and etiology is recommended 4
Iron deficiency management is independent of lipid management and should be addressed concurrently 3

Counseling all patients on lifestyle modifications, including weight control, increased physical activity, alcohol moderation, sodium reduction, and emphasis on fresh fruits, vegetables, and low-fat dairy products, is recommended for blood pressure control 1, 4
Monitoring blood pressure at every visit is advised 1
Providing comprehensive tobacco cessation counseling at every visit is recommended for smoking cessation 1

Considering pharmacotherapy if LDL-C remains ≥190 mg/dL after 12 weeks of lifestyle changes (with 0-1 risk factors) is recommended 2
Considering pharmacotherapy if LDL-C remains ≥160 mg/dL after 12 weeks of lifestyle changes (with 2+ risk factors and 10-year risk <10%) is recommended 2
Considering pharmacotherapy if LDL-C remains ≥130 mg/dL after 12 weeks of lifestyle changes (with 2+ risk factors and 10-year risk 10-20%) is recommended 2
Considering pharmacotherapy if patient has CHD or CHD equivalent and LDL-C remains ≥130 mg/dL after lifestyle changes is strongly recommended 2

The American College of Cardiology recommends limiting total fat to 25-35% of total calories, with saturated fat <7%, trans fat <1%, and the remainder from unsaturated fats for patients with hypercholesterolemia on pravastatin and ezetimibe aiming for LDL-C <70 mg/dL 6, 7
The American College of Cardiology suggests that saturated fat should be <7% of total calories for patients with hypercholesterolemia on pravastatin and ezetimibe aiming for LDL-C <70 mg/dL 6, 7
The American College of Cardiology recommends that trans fat should be <1% of total calories, essentially zero, for patients with hypercholesterolemia on pravastatin and ezetimibe aiming for LDL-C <70 mg/dL 6, 7
The American Heart Association recommends including omega-3 fatty acids from fish or fish oil capsules (1 g/day) for additional cardiovascular risk reduction for patients with hypercholesterolemia on pravastatin and ezetimibe aiming for LDL-C <70 mg/dL 6
The American College of Cardiology recommends limiting dietary cholesterol to <200 mg/day for patients with hypercholesterolemia on pravastatin and ezetimibe aiming for LDL-C <70 mg/dL 6, 7

The American College of Cardiology suggests that if patients do not achieve LDL-C <70 mg/dL on maximally tolerated pravastatin plus ezetimibe with dietary changes, intensification with a PCSK9 inhibitor becomes reasonable 8, 9